Automated Method Fuses MRI and SPECT Prostate Images

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 7
Volume 9
Issue 7

ST. LOUIS-An automated technique for coregistering MRI or CT images with SPECT (single photo emission computed tomography) images has the potential to improve the accuracy of prostate cancer staging, according to research presented at the Society of Nuclear Medicine 47th Annual Meeting.

ST. LOUIS—An automated technique for coregistering MRI or CT images with SPECT (single photo emission computed tomography) images has the potential to improve the accuracy of prostate cancer staging, according to research presented at the Society of Nuclear Medicine 47th Annual Meeting.

Sophisticated Software

Zhenghong Lee, PhD, D. Bruce Sodee, MD, and their colleagues at University Hospitals of Cleveland/Case Western Reserve University used sophisticated new software to automatically coregister results with SPECT imaging of ProstaScint (a monoclonal antibody labeled with indium-111) and MRI in prostate cancer patients.

The resulting image shows the site of SPECT metabolic activity superimposed on the same MRI-defined anatomic slice. The researchers have also used the technique to coregister SPECT and CT prostate cancer images.

The software maximizes Mutual Information, or relative entropy between the two volumes, to calculate the optimal alignment of the SPECT/ProstaScint and MRI images.

Virtual 3D Presentation

Data from this “fused” image is presented in virtually three dimensions, or virtual 3D. “The result,” Dr. Sodee said, “is a significantly clearer image of the tumor’s size and exact location.”

The 3D virtual software will also have applications in coregistering PET (positron emission tomography) images of metabolic cancer activity with anatomic CT or MRI correlation, Dr. Lee said.

Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Related Content